Burning Rock Biotech Stock News

Brokerages forecast that Burning Rock Biotech Limited (NASDAQ:BNR) will announce earnings per share (EPS) of $0.12 for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Burning Rock Biotechs earnings. Burning Rock Biotech posted earnings of ($0.23) per share in the same quarter last year, which suggests a positive year-over-year growth []

Burning Rock Biotech Limited (NASDAQ:BNR) was the recipient of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 1,660,000 shares, a decrease of 19.8% from the October 31st total of 2,070,000 shares. Currently, 1.9% of the companys stock are sold short. Based on an []

Burning Rock Biotech Limited (NASDAQ:BNR)s share price reached a new 52-week low on Friday . The company traded as low as $11.74 and last traded at $11.83, with a volume of 8258 shares changing hands. The stock had previously closed at $12.98. A number of research firms have weighed in on BNR. Zacks Investment Research []

Zacks Investment Research lowered shares of Burning Rock Biotech (NASDAQ:BNR) from a hold rating to a strong sell rating in a research note released on Tuesday morning, Zacks.com reports. According to Zacks, Burning Rock Biotech Limited focuses on the application of next generation sequencing technology in the field of precision oncology. Its business consists of []

Burning Rock Biotech Limited (NASDAQ:BNR)s stock price dropped 5.1% during mid-day trading on Monday . The stock traded as low as $16.27 and last traded at $16.27. Approximately 4,040 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 330,318 shares. The stock had previously closed at $17.14. BNR []

Price T Rowe Associates Inc. MD trimmed its stake in shares of Burning Rock Biotech Limited (NASDAQ:BNR) by 23.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 557,334 shares of the companys stock after selling 167,339 shares during []

Key Takeaways: Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due to latest Covid-related travel restrictions in China

Shares of Burning Rock Biotech Limited (NASDAQ:BNR) were up 10.8% during mid-day trading on Tuesday . The stock traded as high as $15.23 and last traded at $15.23. Approximately 12,323 shares changed hands during trading, a decline of 96% from the average daily volume of 328,569 shares. The stock had previously closed at $13.75. Several []

Burning Rock Biotech (NASDAQ:BNR) posted its quarterly earnings data on Sunday. The company reported ($1.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of ($1.61) by ($0.03), MarketWatch Earnings reports. Burning Rock Biotech had a negative return on equity of 27.95% and a negative net margin of 134.93%. During the []

The ARK Genomic Revolution ETF ARKG, +2.01% started a position in Burning Rock Biotech BNR, +10.69% , a Chinese cancer sequencing technology company that jumped 11% after reporting third-quarter resul

Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q3 2021 Results - Earnings Call Transcript

Key Prominent Players Covered in the US Genetic Testing Market are Invitae Corporation (San Francisco, U.S.), Ambry Genetics (Aliso Viejo, U.S.), BioReference Laboratories, Inc. (Elmwood Park, U.S.), Progenity, Inc. (San Diego, U.S.), Quest Diagnostics Incorporated (Secaucus, U.S.), Myriad Genetics, Inc. (Salt Lake City, U.S.), Fulgent Genetics (Temple City, U.S.), Burning Rock Biotech Limited (Guangzhou, China) Key Prominent Players Covered in the US Genetic Testing Market are Invitae Corporation (San Francisco, U.S.), Ambry Genetics (Aliso Viejo, U.S.), BioReference Laboratories, Inc. (Elmwood Park, U.S.), Progenity, Inc. (San Diego, U.S.), Quest Diagnostics Incorporated (Secaucus, U.S.), Myriad Genetics, Inc. (Salt Lake City, U.S.), Fulgent Genetics (Temple City, U.S.), Burning Rock Biotech Limited (Guangzhou, China)